Allergic rhinitis: pharmacotherapy in pregnancy and old age

Ridolo, Erminia; Caminati, Marco; Martignago, Irene; Melli, Valerie; Salvottini, Chiara; Riggio, Oliviero; Dama, Annarita; Schiappoli, Michele; Bovo, Chiara; Incorvaia, Cristoforo; Senna, Gianenrico

doi:10.1080/17512433.2016.1189324

Cited by 11 publications

(10 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anyhow, clinical conditions that are considered absolute or relative contraindications are quite frequent in this age population and can interfere with AIT effectiveness and safety. The risk/benefit ratio must be carefully evaluated for each patient, taking into account that in the elderly the frequent occurrence of co-morbidities and the consequent need of daily-based multidrug regimen can favor adverse effects as well as drug interactions [ 49 ]. An important issue concern the ability of AIT, particularly SLIT, to significantly improve the quality of life, reducing symptoms and drugs consumption [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

How to fit allergen immunotherapy in the elderly

et al. 2017

View full text Add to dashboard Cite

Asthma, allergic rhinitis (AR) and atopic dermatitis are very common in young people, but in the latest decades it was increasingly recognized that also individuals of higher ages, including the population over 65 years, are concerned. Actually, it is now acknowledged the aging does not considerably alter the immune response to allergens. Allergen immunotherapy (AIT) is the only treatment that works on the causes of allergy, but elderly people are commonly excluded from AIT, except the cases of insect sting allergy. A number of recent studies showed that aged individuals also successfully respond to AIT for respiratory allergy. Therefore, there is no reason to exclude elder patients from AIT. Anyhow, clinical conditions that are considered absolute or relative contraindications are quite frequent in this aged population, thus the risk/benefit ratio must be carefully evaluated for each patient, taking into account that the more frequent occurrence of co-morbidities and the consequent need of daily-based multidrug regimen can favor adverse effects. An important issue concern the ability of AIT, and particularly of sublingual immunotherapy, to significantly improve the quality of life, that often is particularly impaired in the elderly, reducing symptoms and drugs consumption.

show abstract

Section: Discussionmentioning

confidence: 99%

How to fit allergen immunotherapy in the elderly

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The use of decongestants during pregnancy, particularly in the first trimester, may lead to anomalies such as gastroschisis, endocardial cushion defect, ear anomalies and pyloric stenosis. Therefore, their use is not recommended during pregnancy ( 618 ).…”

Section: Treatment Of Allergic Rhinitismentioning

confidence: 99%

Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)

Ecevit¹,

Özcan²,

Can³

et al. 2021

TAO

View full text Add to dashboard Cite

Object: To prepare a national guideline for Otorhinolaryngologist who treat allergic rhinitis patients. Methods: The study was conducted by three authors, namely the writing support team. The support team made the study plan, determined the writing instructions, chose the subgroups including the advisory committee, the advisors for authors and the authors. A workshop was organized at the very beginning to explain the details of the study to the team. Advisors took the chance to meet their coworkers in their subgroups and determined the main headings and subheadings of the guideline, together with the authors. After key words were determined by the authors, literature search was done in various databases. The authors keep in touch with the advisors and the advisors with the advisory committee and the support group at every stage of the study. National and International published articles as well as the abstracts of unpublished studies, imperatively presented in National Congresses, were included in this guideline. Only Guideline and meta-analyses published in last seven years (2013-2017) and randomized controlled studies published in last two years (2015-2017) were included. After all work was completed by the subgroups, support team brought all work together and edited the article. Results: A detailed guideline about all aspects of allergic rhinitis was created. Conclusion: The authors believe that this guideline will enable a compact and up-to-date information on allergic rhinitis to healthcare professionals. This guideline is the first in the field of Otolaryngology in Turkey. It should be updated at regular intervals.

show abstract

“…The primary non-pharmacological strategy in AR management is avoiding allergens and irritants ( Ridolo et al., 2016 ). In relation to the elimination of allergens, topical saline irrigations help to reduce symptoms of AR when used alone or together with other drugs ( Ghadersohi and Tan, 2017 ).…”

Section: Therapymentioning

confidence: 99%

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis

et al. 2020

View full text Add to dashboard Cite

Allergic rhinitis/rhinosinusitis (AR) is the most common allergic disease. It affects patients’ quality of life and may influence the severity of lower airway disease such as asthma. Therefore, its treatment is of great importance. AR is treated by a combination of effective approaches; however, in some patients, the disease is uncontrolled. In the last several years, the concept of AR has shifted from increased T helper 2 (Th2) cell signaling and downstream inflammation to disease phenotypes with non-Th2-mediated inflammation. AR is a largely heterogenous group of airway diseases, and as such, research should not only focus on immunosuppressive agents (e.g., corticosteroids) but should also include targeted immunomodulatory pathways. Here, we provide an overview of novel therapies, focusing on the role of phosphodiesterase-4 (PDE4) inhibitors in AR. PDE4 inhibitors are potent anti-inflammatory agents that are used for the treatment of inflammatory airway diseases including AR. The PDE4 inhibitor roflumilast was shown to effectively control symptoms of AR in a randomized, placebo-controlled, double-blinded, crossover study in patients with a history of AR. However, only a few PDE4 inhibitors have proceeded to phase II and III clinical trials, due to insufficient clinical efficacy and adverse effects. Research is ongoing to develop more effective compounds with fewer side effects that target specific inflammatory pathways in disease pathogenesis and can provide more consistent benefit to patients with upper airway allergic diseases. Novel specific PDE4 inhibitors seem to fulfill these criteria.

show abstract

Allergic rhinitis: pharmacotherapy in pregnancy and old age

Cited by 11 publications

References 78 publications

How to fit allergen immunotherapy in the elderly

How to fit allergen immunotherapy in the elderly

Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis

Contact Info

Product

Resources

About